کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
11017137 | 1748460 | 2018 | 17 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
EGFRTHATKACrClVKACYP3A4NOACUFHVTEnon–vitamin K antagonist oral anticoagulantESRDTotal hip arthroplasty - آرتروپلاستی کامل لگنCL/F - CL / FTotal knee arthroplasty - آرتروپلاستی کامل زانوPulmonary embolism - آمبولی ریهvitamin K antagonist - آنتاگونیست ویتامین Kchronic kidney disease - بیماری مزمن کلیویEnd-stage renal disease - بیماری کلیوی در مرحله پایانیVenous thromboembolism - ترومبوآمبولی وریدیDeep vein thrombosis - ترومبوز سیاهرگی عمقیDVT - ترومبوز سیاهرگی عمقیtwice daily - دو بار در روزcytochrome P450 3A4 - سیتوکروم P450 3A4Pharmacodynamics - فارماکودینامیکPharmacokinetics - فارماکوکینتیکAtrial fibrillation - فیبریلاسیون دهلیزیestimated glomerular filtration rate - میزان تصفیه گلومرولی برآورد شده استCKD - نارسایی مزمن کلیهhazard ratio - نسبت خطرunfractionated heparin - هپارین غیر اشباع شدهBID - پیشنهادCreatinine clearance - کلیرانس کراتینینonce daily - یک بار در روز
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants](/preview/png/11017137.png)
چکیده انگلیسی
With the growing integration of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical practice, questions have arisen regarding their use in special populations, including groups that may have been underrepresented in clinical trials. Patients with renal impairment, particularly in the lower echelons of renal function, are one such group. In an effort to elucidate the current evidence regarding the use of NOACs in patients with renal impairment, a systematic assessment of the literature was performed. The MEDLINE database was interrogated for studies and analyses evaluating the influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of NOACs published from January 1, 2000, through August 2, 2017. The 82 relevant publications retrieved highlight the diversity in the NOAC class regarding the impact of renal function on drug clearance, drug exposures, and clinical trial outcomes. In several large clinical trials, subgroup analyses revealed no significant differences when patients were stratified by creatinine clearance as a measure of renal function. Efficacy findings, in particular, were largely aligned with the overall population in the included studies. However, relative risks of bleeding were shown to vary, sometimes driven by changes in bleeding event rates in the comparator arm (eg, warfarin, enoxaparin). With few exceptions, minimal influence of mild renal impairment was observed on the relative efficacy and safety of NOACs. Taken together, the evidence suggests that the presence of renal impairment merits careful consideration of anticoagulant choice but should not deter physicians from appropriate use of NOACs.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 93, Issue 10, October 2018, Pages 1503-1519
Journal: Mayo Clinic Proceedings - Volume 93, Issue 10, October 2018, Pages 1503-1519
نویسندگان
Matthew R. MD, Reinhold MD,